基于外膜囊泡平台的鼻内流感疫苗候选研究
本研究利用基因工程细菌外膜囊泡(OMV)平台,将重组A型流感病毒血凝素(HA)共价修饰于OMV上,制备鼻内流感疫苗候选。小鼠间隔两周鼻内接种三次后,二次接种即可测到抗原特异性IgG,鼻洗液和肺组织诱导强IgA;攻毒后三天鼻洗液和肺组织检测不到病毒,并预防流感临床症状,表明疫苗诱导强黏膜保护性免疫应答。
要点
- OMV平台可高密度共价装饰重组HA,制备鼻内流感疫苗候选。
- 小鼠三次鼻内接种后,鼻洗液和肺组织诱导强IgA应答。
- 攻毒后三天鼻洗液和肺组织检测不到流感病毒,临床症状被预防。
核心结论
- 鼻内OMV流感疫苗候选可诱导强黏膜免疫和保护性免疫应答。
研究设计与样本
- 临床前小鼠研究:将A/Puerto Rico/8/1934(H1N1)HA在HEK-293-F悬浮细胞中生产并偶联至OMV,纯化后配制于PBS+15%甘油缓冲液。
- 小鼠间隔两周鼻内接种三次,检测免疫应答及流感病毒攻毒保护。
主要发现
- 二次接种后可测到抗原特异性IgG。
- 鼻洗液和肺组织中观察到强IgA诱导。
- 攻毒后三天鼻洗液或肺组织中检测不到流感病毒。
- 疫苗接种预防了流感临床症状。
临床怎么用
- 提示鼻内OMV平台可作为诱导黏膜免疫的流感疫苗开发策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Influenza A vaccines have been used successfully for a long time to prevent disease, but most vaccines are produced using egg-based technologies that cause long production lead times and challenges to match circulating influenza strains. Furthermore, these vaccines are often given as intramuscular injections, which induce systemic immune responses but limited mucosal immunity. Mucosal vaccination strategies have been developed to prevent various air-borne respiratory infections, including influenza. An influenza A vaccine candidate was developed based on Outer Membrane Vesicles (OMVs) derived from genetically engineered bacteria. A plug-and-play-like technology allows for high-density covalent decoration of these OMVs with recombinant antigens to generate highly immunogenic mucosal vaccines. In the present study, the OMV-platform was used for the development of an intranasal influenza A vaccine candidate. Influenza A/Puerto Rico/8/1934 (H1N1) (PR8) hemagglutinin (HA) was produced in HEK-293-F suspension cells and coupled to OMVs. The vaccine substance was purified and formulated in a buffer suitable for mucosal administration, PBS + 15% glycerol. Mice were vaccinated intranasally three times at two-week intervals, and the immune response, as well as protection against influenza virus challenge, was measured. Antigen-specific IgG could be measured after two vaccinations, and a strong induction of IgA was observed in both nasal lavage fluid and lung tissue. Furthermore, influenza virus was non-detectable in nasal lavage or lung tissue three days after viral infection in vaccinated animals. Clinical signs of influenza disease were also prevented by the vaccination, indicating a vaccine-induced protective response. CONCLUSION: The intranasal OMV influenza vaccine candidate induces a strong mucosal and protective immune response.
引用
- Magnusson AC, Lim S, Niemi C, et al. Intranasal influenza vaccination using an outer membrane vesicle platform. Vaccine. 2026. PMID: 42361782. doi:10.1016/j.vaccine.2026.128876
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。